Trial Profile
A Phase 1 Open-Label Study to Evaluate the Pharmacokinetics of Filgotinib in Subjects With Impaired Hepatic Function
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Jan 2021
Price :
$35
*
At a glance
- Drugs Filgotinib (Primary)
- Indications Ankylosing spondylitis; Crohn's disease; Cutaneous lupus erythematosus; Lupus nephritis; Psoriatic arthritis; Rheumatoid arthritis; Sjogren's syndrome; Ulcerative colitis; Uveitis
- Focus Pharmacokinetics
- Sponsors Gilead Sciences
- 15 Jun 2019 Results presented at the 20th Annual Congress of the European League Against Rheumatism
- 12 Oct 2018 Status changed from active, no longer recruiting to completed.
- 10 Aug 2018 Status changed from recruiting to active, no longer recruiting.